Technical Analysis for HCM - Hutchison China MediTech Limited

Grade Last Price % Change Price Change
A 42.79 1.76% 0.74
HCM closed up 1.76 percent on Monday, August 2, 2021, on 57 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical HCM trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week Closing High Bullish 1.76%
180 Bullish Setup Bullish Swing Setup 1.76%
Inside Day Range Contraction 1.76%
New 52 Week High Strength 4.42%
Upper Bollinger Band Touch Strength 4.42%
Crossed Above 20 DMA Bullish 2.34%
180 Bullish Setup Bullish Swing Setup 2.34%
Multiple of Ten Bullish Other 2.34%
Gapped Up Strength 2.34%
Older End-of-Day Signals for HCM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 12 hours ago
Up 2% about 12 hours ago
Upper Bollinger Band Resistance about 12 hours ago
Up 1% about 13 hours ago
Down 1% about 13 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Hutchison China MediTech Limited Description

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People's Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Industry Beverage Pharmaceuticals Drug Discovery Non Small Cell Lung Cancer Clinical Trial Small Cell Lung Cancer Ulcer Colitis Ulcerative Colitis Beauty Care Products Natural Food Clinical Trial Product Crohn's Disease Product Testing Preclinical Stage Product Traditional Chinese Medicine Hematological Cancers Janssen Pharmaceutica Stage Products Medicine Products Natural Products Gastric Cancer Preclinical Stage Products Treatment Of Hematological Cancers Nursing Research

Is HCM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 43.93
52 Week Low 23.67
Average Volume 486,659
200-Day Moving Average 31.32
50-Day Moving Average 34.11
20-Day Moving Average 39.29
10-Day Moving Average 40.71
Average True Range 2.18
ADX 34.8
+DI 39.34
-DI 17.77
Chandelier Exit (Long, 3 ATRs) 37.38
Chandelier Exit (Short, 3 ATRs) 40.78
Upper Bollinger Bands 43.36
Lower Bollinger Band 35.22
Percent B (%b) 0.93
BandWidth 20.72
MACD Line 2.15
MACD Signal Line 2.17
MACD Histogram -0.0213
Fundamentals Value
Market Cap 6.23 Billion
Num Shares 146 Million
EPS -0.66
Price-to-Earnings (P/E) Ratio -64.83
Price-to-Sales 19.32
Price-to-Book 12.45
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.24
Resistance 3 (R3) 45.03 44.02 44.83
Resistance 2 (R2) 44.02 43.39 44.12 44.69
Resistance 1 (R1) 43.40 43.01 43.71 43.61 44.56
Pivot Point 42.39 42.39 42.54 42.49 42.39
Support 1 (S1) 41.77 41.76 42.08 41.98 41.02
Support 2 (S2) 40.76 41.38 40.86 40.89
Support 3 (S3) 40.14 40.76 40.75
Support 4 (S4) 40.35